We Think Some Shareholders May Hesitate To Increase 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation
Unveiling 9 Analyst Insights On 10x Genomics
Ratings for 10x Genomics (NASDAQ:TXG) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their
Express News | Jefferies Initiates Coverage On 10x Genomics With Hold Rating, Announces Price Target of $24
Express News | 10X Genomics Inc : Jefferies Initiates Coverage With Hold Rating; Price Target $24
We're Not Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr
10x Genomics Launches 5,000-Plex Gene Panel for Xenium
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., May 29, 2024 /PRNewswire/ -- 10x Genom
Form 144 | 10x Genomics(TXG.US) Officer Proposes to Sell 100.24K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $10x Genomics(TXG.US)$ Officer Hindson Benjamin J. intends to sell 4,037 shares of its common stock on May 22, with a total market value of approximately $100.24K. Hi
Form 144 | 10x Genomics(TXG.US) Officer Proposes to Sell 125.22K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $10x Genomics(TXG.US)$ Officer Saxonov Serge intends to sell 5,043 shares of its common stock on May 22, with a total market value of approximately $125.22K. Saxonov
10x Genomics Stock Slides Amid German Patent Court Ruling
Express News | German Federal Patent Court Invalidates European Patent No. 2794928b1 In Germany
German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win To NanoString, Now A Bruker Business, Will Seek An End To The Injunction Impacting Sales Of CosMx SMI Products In Germany
NanoString, now a Bruker business, will promptly seek an end to the injunction impacting sales of CosMx SMI products in GermanyBruker Corporation (NASDAQ:BRKR) today announced that the German Federal
Express News | Bruker Corp - German Federal Patent Court Invalidates Patent Asserted by 10X Genomics
Express News | 10X Genomics Inc : Stephens Cuts Target Price to $45 From $62
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)
10x Genomics First Quarter 2024 Earnings: In Line With Expectations
Insider Moves Spark Speculation: 10X Genomics Executives Rethink Stock Sale Strategies
UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating
10x Genomics (TXG) has an average rating of outperform and price targets ranging from $26 to $62, according to analysts polled by Capital IQ. Price: 26.91, Change: -2.37, Percent Change: -8.09
10x Genomics Price Target Cut to $32.00/Share From $57.00 by TD Cowen
10x Genomics Price Target Cut to $32.00/Share From $57.00 by TD Cowen
10x Genomics Is Maintained at Buy by Stifel
10x Genomics Is Maintained at Buy by Stifel
Express News | Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53
No Data